Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AST-120 in moderate to severe chronic kidney disease
NCT00500682Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Jul 2007
- Primary completion
- Oct 2011
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Placebo with AST-120 (2 arms). Primary endpoints: Composite of Dialysis Initiation, Kidney Transplantation, and Serum Creatinine Doubling and Treatment-emergent Adverse Events. Started Jul 2007; status: completed.
02
Drugs
activated charcoal
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT00500682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00500682.